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S320 Poster Session Iwhen compared to pts with normal NS (19.367.8 days, P5\.0001)
and mildly compromised NS (19.568.8 days, P 5\.0001).
Conclusions: Pts with a normal NS prior to transplantation, as de-
fined by the VA-NSCS, have a superior survival rate than pts with
compromised NS prior to APBSCT. Additional studies will be nec-
essary to corroborate the value of the VA-NSCS in determining tox-
icity and outcome after APBSCT.
307
BK VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS IN PEDIATRIC HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
Ardura, M.I.1, DeMasi, J.2, Pavlock, T.2, Simms-Waldrip, T.2, Cox, J.3,
Koh, A.Y.2, Aquino, V.M.2 1Nationwide Children’s Hospital & The Ohio
State University, Columbus, OH; 2Children’s Medical Center Dallas &
UT Southwestern Medical Center, Dallas, TX; 3Huntsville Hospital for
Women and Children, Huntsville, AL
Background: BK Virus-associated hemorrhagic cystitis (BKHC)
has emerged as a serious infection after HSCT, however data in chil-
dren are limited.
Objective: To describe the clinical characteristics, treatment, and
outcomes of BKHC in children after HSCT.
Patients and Methods: Retrospective review of medical records of
children who underwentHSCTat Children’sMedical CenterDallas
from Jan 1, 2006 – July 31, 2011 with evidence of BKHC. Demo-
graphic, clinical, microbiologic, management, and outcome data
was collected.
Results: 20 children (incidence 13%), 9 males, median age 11 y
[range 5-18], developed BKHC a median of 15 days [-2 to 57] post
autologous (1) and allogeneic (19) HSCT: MRD (6), MUD (6),
MMUD (6), syngeneic (1) for ALL (7), AML (4), aplastic anemia
(4), and other conditions (5). Conditioning included busulfan/cyclo-
phosphamide/ATG (10), TBI/thiotepa/cyclophosphamide (9), &
carboplatin, etoposide, melphalan (1). Only 8 (40%) patients had en-
grafted and 7 (35%) were receiving systemic corticosteroids at
BKHC onset. 7 (35%) patients complained of dysuria; 15 (75%)
had moderate to large blood on initial urinalysis, all had BK viruria,
14 (70%) had$ 106 BK copies/mL urine. 6 (30%) had BK viremia at
HC onset, 16 (80%) developed viremia with median peak BK of 10,
850 copies/mL blood [439-1.5 million] on D+42 (7-91), resolving in
11/16 by D+76 [22-134]. There was no correlation between viruria
and viremia at onset (Spearman R 0.41, p 5 0.07). 8 (40%) had ab-
normal initial ultrasounds (5 echogenic debris/clot, 4 bladder wall
thickening). Patients had grade 1 (4), 2 (6), 3 (4), and 4 (6) HC. 14
(70%) patients were already receiving fluoroquinolone prophylaxis
at BKHC onset; 17 (85%) patients received Cidofovir at 1 mg/kg
3x/wk (11), 3mg/kg qwk (1), or 5mg/kg qwk (5) for a median of 62
days [1-119]. 6 (30%) patients developed renal insufficiency requir-
ing CVVH, one patient developed Fanconi’s syndrome; 2 (10%) had
urological interventions for obstruction and bleeding. 7 children
died from other causes. Concomitant infections included: bacter-
emia (5), candidemia (3), peritonitis (2), UTI (2), detectable CMV
(5), EBV (2), and adenovirus (4) viremia.
Conclusions: Incidence of BKHC was high in our HSCT popula-
tion, with most children presenting pre-engraftment. Though
many had clinical and virological resolution, morbidity was not neg-
ligible. Additional data in pediatric BKHC after HSCT is needed to
guide optimal treatment guidelines.308
SAFETY OF PROBIOTIC USAGE IN CHILDREN UNDERGOING HEMATOPOI-
ETIC CELL TRANSPLANTATION (HCT): A PRELIMINARY REPORT
Nieder, M.L.1, Hamblin, F.L.1, Gates, M.S.1, Bhatia, M.2, Petrovic, A.1,
Ladas, E.J.2 1All Children’s Hospital, St Petersburg, FL; 2Columbia Uni-
versity, New York, NY
Myeloablative chemotherapy is associated with prolonged periods
of cachexia/anorexia, nausea/vomiting, mucositis, and compromised
gut integrity (CGI). The toxicities associated with HCT often lead
to prolonged periods of poor oral intake andmay result in overt mal-
nutrition. CGI decreases oral tolerance to foods, reduces QOL and
functional status, delays the transition from the hospital to home set-
ting, and increases the risk of the development of gut-derived infec-tions. CGI may increase the risk of acute graft versus host disease.
Probiotics have emerged as a possible therapeutic agent in preserving
gut integrity. Probiotics can improve the gut dysbiosis, promote cell
survival, improve barrier function, prevent adherence of pathogenic
bacteria, and suppress proinflammatory cytokines. Clinical trials in
adults receiving organ transplants have found that probiotics de-
crease the incidence of infection, decrease the duration of antibiotic
use, and decrease the incidence ofmultiorgan failure and systemic in-
flammation. However, the safety and feasibility of probiotics has not
been investigated among children and adolescents undergoing
HCT. Our ongoing 30-patient trial aims to evaluate/investigate:
-Safety of orally administered Lactobacillus plantarum in children
undergoing myeloablative HCT
-Feasibility of administering the probiotic
-Overall incidence of probiotic bacteremia
-Overall incidence of acute GVHD in patients who received pro-
biotic
Lactobacillus plantarum (strains 299 and 299v; 1 x108 CFU/kg/day)
was given orally or via enteral tube daily from Day -7 through Day +
14 to 7 children. No patients had probiotic bacteremia, 2/7 had non-
lactobacillus bacteremia, 3/7 had C. diff in their stool and all patients
survived through Day + 100. Compliance was excellent. There were
no SAE’s. One unexpected adverse event(AE), acute appendicitis, oc-
curred on Day + 21; pathology showed a mixed, mostly gram-nega-
tive flora and the patient hadC.diff. This AEwas not considered to be
attributable to lactobacillus administration. These preliminary re-
sults suggest that it is feasible to administer this probiotic and lacto-
bacillus bacteremia has not been identified. There are no SAE’s to
date and no Grade 2-4 GVH by Day 28.
Table 1. Preliminary Findings
Age in Non-lactobacillus C.diff by GVH by
Years Donor Compliance SAE bacteremia Day 28 Day 28PT 1 2.11 UCB 91% No Yes Yes 0
PT 2 3.7 MUD 100% No No No 0
PT 3 17 MRD 100% No No Yes 0
PT 4 8.5 MRD 100% No No No 0
PT 5 4 MRD 100% No No Yes 0
PT 6 8.5 UCB 100% No Yes No II
PT 7 3.1 MUD 91% No No No 0309
LOWER BIOAVAILABILITY AND SHORTER HALF-LIFE OF VORICONAZOLE
IN PEDIATRIC BMT PATIENTS
Han, K.1, Windreich, R.2, Venkataramanan, R.1, Rivett, J.2, Zhao, W.1,
Goyal, R.K.2 1University of Pittsburgh, Pittsburgh, PA; 2Children’s Hos-
pital of Pittsburgh, Pittsburgh, PA
Introduction: Voriconazole, a triazole antifungal agent with excel-
lent oral bioavailability has been used for mold prophylaxis in trans-
plant recipients. Lack of detailed pharmacokinetic information in the
pediatric BMT setting has been an impediment to optimal dosing
regimen of this agent in children.
Materials & Methods: Voriconazole pharmacokinetics (PK) pro-
files were evaluated in 20 allogeneic BMT patients. Mean age at
transplant was 9.4 y (0.4-22 y); 12 females, 8 males; all whites. All pa-
tients received initial dose of 7 mg/kg twice daily; doses were ad-
justed to achieve Ctrough $1 mcg/ml. For each patient, eight timed
blood samples were collected on three occasions at steady-state:
the first while on an oral dosing (d-10 to d+2), the second while on
intravenous dosing (d+6 to d+26), and the third after switching to
an oral dosing (d+19 to d+110). Voriconazole plasma concentrations
were measured using HPLC. Pharmacokinetic analysis was per-
formed using NONMEM.
Results: In 54 PK studies, the mean trough concentrations of vori-
conazole before (C0) and at the end of dosing interval (C12) were 1.3,
and 1.2 ug/ml, respectively. Less than half of the voriconazole plasma
concentrations (45.4%) were maintained within 1-6 mg/ml, while
46.2% were below 1mg/ml and 8.4% above 6mg/ml. Voriconazole
concentrations normalized to dose (mean6SD, ng/mL/mg) were:
C0 0.00660.008, Cmax 0.03160.022 and C12 0.004 60.005 ug/ml.
C0 and C12 were similar and correlated well (r
2 5 0.88) indicating
